DUBLIN, January 19, 2022–(BUSINESS WIRE)–The "Hemophilia Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)" report has been added to ResearchAndMarkets.com's offering.
The Hemophilia market is expected to witness a CAGR of 5.9% during the forecast period (2021-2026).
Companies Mentioned
Bayer AG
BioMarin Pharmaceutical, Inc.
CSL Behring
Kedrion S.p.A
Novo Nordisk
Pfizer, Inc.
Roche (Chugai Pharmaceutical Co.)
Sanofi (Genzyme Corporation)
Takeda Pharmaceutical (Shire Plc.)
Genentech
Grifols
Medexus
Octapharma
Key Market Trends
Hemophilia A is Expected to Hold Significant Market Share in the Disease Type Segment
Hemophilia A is the most common severe bleeding disorder. Replacement therapy, providing the missing coagulation factor, has been the mainstay of treatment both prophylactically and to treat bleeding. According to the data published by the World Federation of Hemophilia in 2019, hemophilia is more recorded among males, and approximately 24.6 in 100.000 neonates suffer from hemophilia A.
This is a rare genetic bleeding disorder projected that affected around 157,517 people worldwide in 2019. The key medication to treat hemophilia A is concentrated FVIII product, also known as clotting factor. The recombinant factor products that are developed in a laboratory using DNA technology impede the use of human-derived pools of donor-sourced plasma. Due to the advances in recombinant protein engineering and the introduction of gene therapy and novel strategies to target the coagulation cascade.
North America Dominates the Market and Expected to do Same in the Forecast Period
The North America region dominates the global market. The major factors driving the growth of the hemophilia market in the region include the therapeutic advances in hemophilia, which led to a wave of new FDA-approved agents and increasing awareness about technologically advanced products, increasing prevalence hemophilia, and the presence of a huge patient pool. The United States is the largest market in the region.
According to the World Federation of Hemophilia 2018 report, in 2018, there were about 17,757 people diagnosed with hemophilia in the United States. Furthermore, in 2019, the number of people with hemophilia in the United States increased to about 20,000 individuals, as per NHF (National Health Federation). In the United States, agencies, like hemophilia Association of America, generally offers continuous treatment for patients by introducing different co-pay initiatives. This is further expected to balance the expenditures for patients and assist them in providing access to new products. In the United States, the BioMarin company is conducting Phase III clinical trial with valoctocogene roxaparvovec (BMN 270) to assess the efficacy of BMN 270 in the treatment of hemophilia A.
Therefore, advancements in the gene therapy and novel strategies to target the coagulation factors is expected to drive the market in the near future. In the United States, Genzyme Corporation offers "ALPROLIX" (Coagulation Factor IX (Recombinant), Fc Fusion Protein), an injectable medicine used to help control and prevent bleeding in people with hemophilia B. Thus, the increasing research and development in the development of new effective therapies, along with the rising prevalence of hemophilia in the United States, is expected to drive the market over the forecast period.
Key Topics Covered:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Hemophilia
4.2.2 Favorable Government Initiatives
4.2.3 Rising R&D and New Product Development
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Lack of Awareness Regarding Advanced Technologies
4.4 Porter's Five Force Analysis
5 MARKET SEGMENTATION
5.1 By Disease Type
5.2 By Therapy
5.3 By Product Type
5.4 Geography
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/hvga64
View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005921/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
White House advisor Anthony Fauci said U.S. officials could authorize Pfizer and BioNTech's Covid vaccine for children younger than 5 next month.
The clinical-stage biotech company is working on an antiviral treatment to fight multiple variants of COVID-19.
On Wednesday, the Biden administration announced that it will make 400 million N95 face masks available free of charge to Americans. Here's how to get yours.
Shares of Novocure Limited (NASDAQ: NVCR) are jumping 12.9% higher as of 11:09 a.m. ET on Thursday. The solid gain came after investment firm Truist Financial upgraded the stock from a hold to a buy recommendation. Truist kept its 12-month price target for the stock at $125, which represents upside potential of more than 70%.
Is it the movie theater? The gym? Researchers calculated the odds of infection for any place you might go.
The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma. Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial for SACT-1 in 2022. Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% – 10% of all childhood tumors, accounting for around 15% of all cancer-related deaths in the pediatric population. Aptorum received it
The government plans to distribute free at-home tests to households starting this week. Here's how to get yours.
COVID cases may reach more than one million a day in America, peaking in only a few states while it surges in others. Where exactly will the Omicron variant spread most next? Dr. Anthony Fauci, the chief medical advisor to the President and the director of the National Institute of Allergy and Infectious Diseases, spoke with Yahoo Finance's Anjalee Khemlani about the recent surge in omicron cases within the U.S. Read on for his warnings—and to ensure your health and the health of others, don't m
White House to distribute 400 million free N95 masks at 'tens of thousands' of locations starting next week
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.
Shares of Leap Therapeutics (NASDAQ: LPTX), a clinical-stage biopharmaceutical company, are surging in response to positive clinical results from a stomach cancer study. Last September, Leap Therapeutics stock more than doubled overnight after the company reported impressive response rate data for its lead candidate DKN-1 plus tislelizumab from BeiGene (NASDAQ: BGNE). The experimental combination treatment was tested among patients newly diagnosed with advanced-stage stomach cancer.
(Bloomberg) — Elon Musk’s brain implant company Neuralink is now hiring a clinical trial director, an indication that the company’s longstanding goal of implanting chips in human brains is coming closer.Most Read from BloombergEarly Omicron Breakthroughs Show mRNA Vaccines’ WeaknessJeremy Grantham Doubles Down on Crash Call, Says Selloff Has StartedLate Rout in Tech Sends Nasdaq 100 Into Correction: Markets WrapWhy Some Vaccinated People Resist Omicron and Others Don’tThailand to Resume Quarant
Jenna Jameson, 47, remains in the hospital after doctors ruled out her original diagnosis of Guillain-Barré syndrome. Her partner explained it all on Instagram:
Dry January is a popular New Year's resolution, where people give up booze for a month. But does it offer long-lasting health benefits? Here’s what to know.
One of the most damaging effects of COVID-19 is that for many people, even after a mild infection, certain terrible symptoms never go away. Yesterday on SiriusXM Doctor Radio's "Doctor Radio Reports," CDC Director Rochelle Walensky spoke with show host Dr. Marc Siegel about how the CDC works with pandemic data, in real time, and discussed Long COVID, as well as how long you should quarantine if you get COVID—she also talks about masks. Read on for 5 life-saving pieces of advice—and to ensure you
A Kentucky congressman who has been critical of pandemic mask and vaccine mandates said he has tested positive for COVID-19. Rep. Thomas Massie, a Republican from northern Kentucky, tweeted Thursday that he is not vaccinated but his symptoms have been mild and he believes he is “over it.” Massie said on Twitter he would not be voting, meeting anyone in person or making public appearances until next week.
Will coronavirus be eradicated? 'No, it will not,' says Dr. Gregory Poland, who studies the immunogenetics of vaccine response at the Mayo Clinic.
The Biden administration aims to make 400 million N95 masks available to all Americans for free at pharmacies and community health centers next week, a White House official said per The Wall Street…
The CDC now says the general public can wear N95 masks. But how many times can you use them? Experts break it down and share how to store and extend the life of your face mask.
The National Institutes of Health on Wednesday updated its COVID-19 treatment guidelines for patients with mild to moderate forms of COVID-19 who are at high risk for disease progression. The new guidelines now include the recently authorized antivirals developed by Pfizer Inc. (pfe) and Merck & Co. Inc. (mrk) /Ridgeback Biotherapeutics, note that GlaxoSmithKline (gsk) and Vir Biotechnology Inc.'s (vir) sotrovimab is the only monoclonal antibody that is thought to be effective against omicron, and have added a three-day course of Gilead Sciences Inc.'s (gild) Veklury as a treatment option.